Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening
Stefan Gradl, H. Steuber, Joerg Weiske, et al.
SLAS DISCOVERY (2021) Vol. 26, Iss. 8, pp. 947-960
Open Access | Times Cited: 21

Showing 21 citing articles:

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
Ruiqi Liu, Jiajun Wu, H. Henry Guo, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 108
Optimizing drug discovery: Surface plasmon resonance techniques and their multifaceted applications
Biswajeet Acharya, Amulyaratna Behera, Suchismeeta Behera
Chemical Physics Impact (2023) Vol. 8, pp. 100414-100414
Open Access | Times Cited: 44
Differential scanning fluorimetry followed by microscale thermophoresis and/or isothermal titration calorimetry as an efficient tool for ligand screening
Maria Winiewska‐Szajewska, Jarosław Poznański
Biophysical Reviews (2025) Vol. 17, Iss. 1, pp. 199-223
Open Access | Times Cited: 1
Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases
Alyssa Padilla, John F. Manganaro, Lydia Huesgen, et al.
Molecules (2023) Vol. 28, Iss. 4, pp. 2000-2000
Open Access | Times Cited: 12
SMYD3 drives cell cycle and epithelial-mesenchymal transition pathways through dual gene transcriptional repression and activation in HPV-negative head and neck cancer
Madhavi Murali, Abbas Saeed, Sohyoung Kim, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
SMYD family in cancer: epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance
Tae‐Su Han, Dae‐Soo Kim, Mi‐Young Son, et al.
Experimental & Molecular Medicine (2024)
Open Access | Times Cited: 3
Histone Lysine Methylation Modification and Its Role in Vascular Calcification
Ye-Chi Cao, Su‐Kang Shan, Bei Guo, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 13
SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
Shanshan Wang, Xin You, Xiaoshu Liu, et al.
iScience (2023) Vol. 26, Iss. 7, pp. 106994-106994
Open Access | Times Cited: 8
A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter
Qian Ding, Jianghong Cai, Jin Li, et al.
MedComm (2024) Vol. 5, Iss. 10
Open Access | Times Cited: 2
Methyltransferases in cancer drug resistance: Unlocking the potential of targeting SMYD3 to sensitize cancer cells
Paola Sanese, Candida Fasano, Martina Lepore Signorile, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189203-189203
Open Access | Times Cited: 2
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor
Antonius ter Laak, R.C. Hillig, Steven Ferrara, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19282-19303
Open Access | Times Cited: 2
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3
Marco Parenti, Marina Naldi, Elisabetta Manoni, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114683-114683
Closed Access | Times Cited: 11
Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy
Hongping Zhu, Jinlong Chai, Rui Qin, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 115009-115009
Closed Access | Times Cited: 8
Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications
Teresa Rubio‐Tomás
Molecular Biology Reports (2021) Vol. 48, Iss. 11, pp. 7499-7508
Closed Access | Times Cited: 8
Design, synthesis, and biological evaluation of SMYD3 inhibitors possessing N-thiazole benzenesulfonamide moiety as potential anti-cancer agents
Suaad A. Audat, Nizar A. Al‐Shar’i, Buthina A. Al-Oudat, et al.
Journal of Saudi Chemical Society (2022) Vol. 26, Iss. 3, pp. 101482-101482
Open Access | Times Cited: 5
Screening of Buffers and Additives for Protein Stabilization by Thermal Shift Assay: A Practical Approach
Filipa S. S. Engrola, João Paquete-Ferreira, Teresa Santos‐Silva, et al.
Methods in molecular biology (2023), pp. 199-213
Closed Access | Times Cited: 2
Interaction of benzenesulfonamide derivatives with Smyd3 using a theoretical model
López‐Ramos Maria, Figueroa‐Valverde Lauro, Marcela Rosas-Nexicapa, et al.
Brazilian Journal of Science (2023) Vol. 3, Iss. 1, pp. 115-129
Open Access | Times Cited: 1
Targeting Non-histone Methylation in Gastrointestinal Cancers: From biology to clinic
Zhanbo Sun, Lixian Liu, Jun Chen
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116802-116802
Closed Access
Protein Lysine Methyltransferases Inhibitors
Ying Li, Lei Ding, Shuang Ren, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 27, pp. 3060-3089
Closed Access | Times Cited: 2
Applications of Biophysics in Early Drug Discovery
Geoffrey A. Holdgate, Christian Bergsdorf
SLAS DISCOVERY (2021) Vol. 26, Iss. 8, pp. 945-946
Open Access | Times Cited: 1
Therapeutics and Diagnostics Discovery
Daria Mochly‐Rosen, Kevin Grimes, Rami N. Hannoush, et al.
Springer eBooks (2023), pp. 33-100
Closed Access
Page 1

Scroll to top